CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
4.442 EUR
-0.07 (-1.55%)
5CV gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 78 industry peers in the Biotechnology industry. 5CV has an excellent financial health rating, but there are some minor concerns on its profitability. 5CV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
5CV had positive earnings in the past year.
5CV had a positive operating cash flow in the past year.
5CV had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of 5CV (28.11%) is better than 93.59% of its industry peers.
5CV's Return On Equity of 33.02% is amongst the best of the industry. 5CV outperforms 94.87% of its industry peers.
Looking at the Return On Invested Capital, with a value of 28.35%, 5CV belongs to the top of the industry, outperforming 98.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 5CV (37.93%) is better than 91.03% of its industry peers.
With an excellent Operating Margin value of 40.58%, 5CV belongs to the best of the industry, outperforming 96.15% of the companies in the same industry.
5CV has a Gross Margin of 94.81%. This is amongst the best in the industry. 5CV outperforms 91.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 5CV is creating value.
Compared to 1 year ago, 5CV has about the same amount of shares outstanding.
Compared to 5 years ago, 5CV has more shares outstanding
5CV has a better debt/assets ratio than last year.
2.2 Solvency
5CV has an Altman-Z score of 9.34. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
5CV has a better Altman-Z score (9.34) than 85.90% of its industry peers.
5CV has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
The Debt to FCF ratio of 5CV (0.18) is better than 93.59% of its industry peers.
5CV has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
5CV has a better Debt to Equity ratio (0.05) than 67.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.34 |
ROIC/WACC3.95
WACC7.17%
2.3 Liquidity
A Current Ratio of 6.17 indicates that 5CV has no problem at all paying its short term obligations.
With an excellent Current ratio value of 6.17, 5CV belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
A Quick Ratio of 6.16 indicates that 5CV has no problem at all paying its short term obligations.
5CV has a Quick ratio of 6.16. This is amongst the best in the industry. 5CV outperforms 87.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 170.16% over the past year.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
5CV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
5CV is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
5CV is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.88% yearly.
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.11, the valuation of 5CV can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 96.15% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.47. 5CV is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.11 | ||
| Fwd PE | N/A |
4.2 Price Multiples
5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 94.87% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 5CV is valued cheaper than 94.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.1 | ||
| EV/EBITDA | 2.83 |
4.3 Compensation for Growth
5CV has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as 5CV's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (11/21/2025, 7:00:00 PM)
4.442
-0.07 (-1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.00B
Revenue(TTM)510.51M
Net Income(TTM)193.64M
Analysts72.31
Price Target4.12 (-7.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.64%
PT rev (3m)-2.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-275%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)220.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.11 | ||
| Fwd PE | N/A | ||
| P/S | 1.96 | ||
| P/FCF | 5.1 | ||
| P/OCF | 4.9 | ||
| P/B | 1.71 | ||
| P/tB | 1.78 | ||
| EV/EBITDA | 2.83 |
EPS(TTM)0.87
EY19.59%
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)0.87
FCFY19.61%
OCF(TTM)0.91
OCFY20.4%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.34 |
F-Score9
WACC7.17%
ROIC/WACC3.95
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / 5CV.DE FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE.
Can you provide the valuation status for CUREVAC NV?
ChartMill assigns a valuation rating of 5 / 10 to CUREVAC NV (5CV.DE). This can be considered as Fairly Valued.
What is the profitability of 5CV stock?
CUREVAC NV (5CV.DE) has a profitability rating of 6 / 10.
What is the financial health of CUREVAC NV (5CV.DE) stock?
The financial health rating of CUREVAC NV (5CV.DE) is 9 / 10.